Imunon, Inc. - Common Stock IMNN 深 滬
已收盤 09-19 16:00:00 美东时间
4.98
-0.120
-2.35%
華盛通- 最 高5.244
- 今 開5.11
- 成交量 44.86万股
- 最 低 4.70
- 昨 收 5.10
- 總市值 1255.56万
- 52周最高 41.2174
- 市盈率 靜 --
- 換手率 17.79%
- 52周最低 4.70
- 委 比 -50.86%
- 總股本 252.12万
- 歷史最高 25857.3851
- 量 比 6.45
- 振 幅 10.67%
- 歷史最低 4.70
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IMUNON To Present New Translational Data From Phase 2 OVATION 2 Study Of IMNN-001 At 2025 AACR Special Conference In Cancer Research
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3
09-19 20:07
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
IMUNON, a clinical-stage biotech company, is advancing its DNA-mediated immunotherapy IMNN-001 in a pivotal Phase 3 trial for treating advanced ovarian cancer. New translational data from the Phase 2 OVATION 2 Study will be presented at the AACR Special Conference. IMNN-001, based on TheraPlas® technology, delivers IL-12 via nanoparticles to activate anti-cancer immunity. Phase 2 results showed significant improvements in overall and progression-...
09-19 12:05
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
IMUNON, a clinical-stage biotechnology company, announced that a pre-recorded presentation will be available online starting September 5, 2025, as part of the H.C. Wainwright Global Investment Conference. The presentation will be accessible via webcast for 90 days. IMUNON’s management will also hold in-person investor meetings from September 8-10. The company focuses on DNA-mediated immunotherapies, including its lead program IMNN-001 for ovarian...
09-02 12:05
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
IMUNON, Inc. (Nasdaq: IMNN) has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued trading on the Nasdaq Capital Market. The company highlighted recent progress, including a 15% stock dividend, Phase 2 OVATION 2 trial results for its DNA-based immunotherapy IMNN-001 targeting advanced ovarian cancer, and the initiation of the Phase 3 OVATION 3 trial. IMUNON focuses on innovative DNA-mediated immunotherapies and ha...
08-28 12:05
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
IMUNON Inc. (Nasdaq: IMNN) announced a 15% stock dividend for shareholders of record as of August 7, 2025, alongside updates on its Phase 3 clinical development of IMNN-001 for ovarian cancer. The company highlighted progress in its OVATION 3 trial, which enrolled its first patient on July 25, 2025, with a flexible enrollment strategy targeting HRD-positive patients. IMUNON also reported financial strength, raising over $3 million and implementin...
08-05 20:00
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
### Summary IMUNON Inc. reported financial results for the second quarter and first half of 2025, highlighting progress in advancing its Phase 3 clinical development of IMNN-001 for newly diagnosed advanced ovarian cancer. The company announced a 15% stock dividend to shareholders, reflecting confidence in its clinical programs and long-term growth strategy. Additionally, the first patient was dosed in the Phase 3 OVATION 3 Study of IMNN-001. Th...
08-05 12:00
Insights into Imunon's Upcoming Earnings
Imunon (NASDAQ:IMNN) is preparing to release its quarterly earnings on Tuesday,...
08-05 05:03
IMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?
Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001.
07-30 23:48
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON Inc. announced the initiation of its pivotal Phase 3 OVATION 3 Study for IMNN-001, a DNA-mediated immunotherapy, in women with newly diagnosed advanced ovarian cancer. The first patient has been dosed, marking a significant milestone. IMNN-001 has shown promising results in earlier trials, improving overall survival and reducing recurrence rates. The Phase 3 trial will assess its safety and efficacy compared to standard chemotherapy. IMUNO...
07-30 12:05
